On September 12, 2023, the Health Sciences Authority (HSA) in Singapore granted authorization for the updated Pfizer Comirnaty vaccine to be employed in Singapore as a preventive measure against Coronavirus Disease 2019 (COVID-19) for individuals aged 6 months and older.
The revised vaccine is an enhanced iteration of the original Comirnaty Vaccine, designed to specifically target the present Omicron subvariants. This modification ensures that the vaccine maintains its protective efficacy as the virus undergoes changes. In compliance with global recommendations, the updated vaccine consists of a monovalent (single) component tailored to match the Omicron XBB.1.5 variant. There have been no alterations to the vaccine’s quality, safety, and effectiveness, and it is anticipated to uphold the favorable balance between benefits and risks observed with the initial Comirnaty Monovalent Vaccine.
When evaluating the updated vaccine, the HSA took into account a wealth of data gathered from prior versions of the Comirnaty Vaccine, alongside additional data demonstrating the updated vaccine’s capacity to bolster immune responses against prevailing Omicron subvariants such as XBB.1.5, EG.5 (Eris), and the emerging BA.2.86. Drawing upon the collective body of evidence and with the backing of the Medicines Advisory Committee and the Panel of Infectious Diseases Experts, the HSA has determined that the overall data supports the authorization of the updated Comirnaty Vaccine.
Given the continual evolution of SARS-CoV-2 and the emergence of novel variants, it is imperative to regularly update approved COVID-19 vaccines to ensure their sustained effectiveness. Such updates may encompass changes in viral strain, antigen, or coding sequence, in accordance with international guidelines. This approach is not novel and mirrors the established practice for seasonal influenza vaccines, which are routinely adjusted every six months.
In line with the protocol for all vaccines and medications registered in Singapore, the HSA will remain vigilant in monitoring and evaluating evolving data on efficacy and safety. This proactive monitoring is essential to confirm that the benefits of the vaccine continue to outweigh the known risks.
COVID-19: Coronavirus Disease 2019
Link to the official press release: https://www.hsa.gov.sg/announcements/press-release/hsa-authorises-updated-comirnaty-targeting-omicron-subvariants
Explore the extensive selection of products at POM Marketplace.
Login or Sign Up for an account today!
* Access to POM Marketplace is available to qualified healthcare professionals only.
Disclaimer: The information provided on this website is intended for informational purposes only, and while we strive for accuracy, POMConnect assumes no liability for errors or omissions. The content should not be considered a substitute for professional medical advice. Always consult with a qualified healthcare provider regarding any medical concerns. POMConnect not endorse specific treatments or external websites linked from this site. POM Marketplace is accessible exclusively to qualified healthcare professionals. Any unauthorized access or use by individuals who do not meet this criteria is prohibited.
